Prostate Cancer | Tumor

CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.

Aggressive Radiation Therapy Improves Survival in Patients with Metastatic Cancer

October 23rd 2018

A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.

Discussing Hereditary Cancer Risk With Children

October 22nd 2018

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

Men with Genetic Mutations: What You Need to Know

October 20th 2018

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

Rubraca Granted Breakthrough Designation for Prostate Cancer

October 2nd 2018

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

CURE's Top 5 Stories: September 2018

October 1st 2018

Here are the top 5 CURE stories for September 2018.

Know the Basics: Prostate Cancer

September 19th 2018

Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.

Knowledge About Inherited Gene Mutations Is Changing Prostate Cancer Treatment

September 1st 2018

Family history was one indicator that a man should undergo periodic screening, but it wasn’t until a couple of decades ago that scientists confirmed a link between inherited mutations of the BRCA gene and the development of prostate cancer.

FDA Approves Xtandi for Non-Metastatic Castration-Resistant Prostate Cancer

July 16th 2018

Deciding Best Next Steps in Prostate Cancer Treatment

July 5th 2018

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

CURE's Top 5 Stories: June 2018

July 2nd 2018

Take a look at the top five CURE stories of June 2018 in this video.

Prostate Cancer: To Treat or Not to Treat

June 27th 2018

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

When Facing Metastatic Prostate Cancer, Know What to Ask Your Doctor

June 20th 2018

There are some key discussions that men with metastatic prostate cancer should have with their health care providers.

Advocacy Groups Collaborate in the Fight Against Prostate Cancer

June 12th 2018

It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.

FDA Approves Paxman Cooling Cap for Solid Tumors

June 12th 2018

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Survivor Discusses Exciting Advancements in Prostate Cancer

June 7th 2018

Over the past few decades, prostate cancer has become better understood and treated more effectively.

HIFU Procedure Keeps High School Ref in the Game After Prostate Cancer Diagnosis

May 24th 2018

FDA Approves Combination Treatment for Metastatic Prostate Cancer

May 24th 2018

The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC), according to Sun Pharma, the company commercializing the treatment.

Prostate Cancer Advocacy Groups See Knowledge Gaps Concerning Disease Stages and Related Treatment Options

May 23rd 2018

The group came together to discuss gaps in knowledge concerning the prostate cancer journey, including nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic disease.

Kristen Bell Helps to Honor Caregivers in TRUE Love Campaign

April 10th 2018

As part of the Prostate Cancer Foundation’s first annual campaign, Kristen Bell selected two winners because of their ‘candor and honesty’ to be honored.

Fans for the Cure

April 5th 2018

After his own journey with prostate cancer, radio and TV personality Ed Randall used his extensive connections throughout professional sports to spread awareness about prostate cancer through his nonprofit organization Fans for the Cure.

Wives of Men with Prostate Cancer Express Concerns with Their 'New Normal' Too

April 2nd 2018

Women felt that they could not show emotions of fear or vulnerability in front of their husbands or children.

Shining a Spotlight on Prostate Cancer

March 29th 2018

What do Bill Nye the Science Guy, fashion designer Michael Kors and one very special prostate cancer advocate all have in common? Blue jackets, a runway and the ultimate goal of raising awareness for prostate cancer.

Xtandi Granted Priority Review for Prostate Cancer Treatment

March 20th 2018

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

Blue Jacket Fashion Show Shines Spotlight on Prostate Cancer

March 14th 2018

With just one catwalk, the Prostate Cancer Foundation brought together celebrities, fashion designers and a special patient advocate to raise awareness for prostate cancer.

FDA Approves Erleada for Nonmetastatic Castration-Resistant Prostate Cancer

February 15th 2018

The Food and Drug Administration (FDA) approved Erleada (apalutamide) for the treatment of patients who have nonmetastatic castration-resistant prostate cancer (CRPC). The drug is now the first FDA-approved treatment in this setting.

Testing for Inherited Gene Mutations in Prostate Cancer Equally Important

February 10th 2018

More than 12 percent of men with prostate cancer tested positive for hereditary mutations of cancer-causing genes, according to study results presented at the 2018 Genitourinary Cancers Symposium.

FDA Approves Zytiga for High-Risk Prostate Cancer

February 8th 2018

Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk castration-sensitive prostate cancer.

Whole Milk Consumption Increases Risk for Prostate Cancer Progression

January 2nd 2018

A study of 1,334 men diagnosed with non-metastatic prostate cancer showed a significantly increased risk of recurrence in those who consumed more than four servings of whole milk per week.

3-D Simulation Helps Patients See Radiation Therapy Plan Firsthand

December 29th 2017

The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.

Apalutamide Granted Priority Review for Castration-Resistant Prostate Cancer

December 21st 2017

The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.